Germline testing is warranted, as we see a high frequency of germline FANCC mutations.<h4>Patient summary</h4>Our study highlights the rate of FANCC mutation in kidney cancer, which may be a therapeutic target and awaits further assessment and drug development. This evidence concerns the gene FANCC and kidney cancer.